![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Molecular Pharmacology Limited (PK) | USOTC:MLPH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0007 | 0.0008 | 0.0007 | 0.00 | 15:05:08 |
OMB APPROVAL |
OMB Number: 3235-0063 |
Expires: May 31, 2014 |
Estimated average burden
hours per response: 2,103.39 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/AMENDMENT NO. 2
(Mark One) | |||||||||||
X |
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||||||||
For the year ended June 30, 2011 | |||||||||||
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |||||||||||
For the transition period from___________ to __________ | |||||||||||
Commission file number 000-50156 | |||||||||||
MOLECULAR PHARMACOLOGY (USA) LIMITED |
|||||||||||
(Exact name of registrant as specified in its charter)
|
|||||||||||
NEVADA |
71-0900799 |
||||||||||
(State or other jurisdiction of
|
(I.R.S. Employer
|
||||||||||
Drug Discovery Centre, 284 Oxford Street, Leederville 6007 Perth, Western Australia |
|||||||||||
(Address of principal executive offices) |
(Zip Code) |
||||||||||
Registrant's telephone number, including area code |
011-61-8-9443-3011 |
||||||||||
Securities registered pursuant to Section 12(b) of the Act: |
|||||||||||
Title of each class |
Name of each exchange on which registered |
||||||||||
Not Applicable |
Not Applicable |
||||||||||
Securities registered pursuant to Section 12(g) of the Act: |
|||||||||||
Common Stock with a par value of $0.001 per share |
|||||||||||
Indicate by check mark if the registrant is a well known seasoned issuer, as defined by Rule 405 of the Securities Act | Yes o | No x | |||||||||
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act | Yes x | No o | |||||||||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding12 months (or for such shorter period that the registrant was required to file such reports), and | |||||||||||
(2) has been subject to such filing requirements for the past 90 days. | Yes x | No o | |||||||||
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (S 232.405 of this chapter) during the preceding 12 | |||||||||||
months (or for such shorter period that the registrant was required to submit and post such files). Not Applicable . | Yes o | No o | |||||||||
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (S 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements | |||||||||||
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Not Applicable . | Yes o | No o | |||||||||
i
Indicate by check mark whether the registrant is large accelerated filer, an accelerated filer, a non accelerated filer, or a small reporting company. See the definitions of "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (Check one): | |||||
Large accelerated filer o | Accelerated filer o | ||||
Non-accelerated filer o | Smaller reporting company x | ||||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act) | Yes o | No x | |||
State the aggregate market value
of the voting and non-voting common equity held by non-affiliates computed by
reference to the price at which the common equity was last sold, or the
average bid and asked price of such common equity, as of the last business day
of the registrant's most recently completed second fiscal quarter.
|
|||||
23,553,740 common shares @ $0.0051 (1) = $120,124.07 |
|||||
(1) Last close price on June 30, 2011 |
|||||
APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY
|
|||||
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the | |||||
Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court | Yes o | No o | |||
Not Applicable . |
|||||
(APPLICABLE ONLY TO CORPORATE REGISTRANTS) |
|||||
Indicate the number of shares outstanding of each of the Registrant's classes of common stock, as of the latest practicable date. | |||||
111,553,740 common shares issued and outstanding as of September 7, 2011. |
|||||
DOCUMENTS INCORPORATED BY REFERENCE |
|||||
None . |
|||||
ii
Exhibit | ||
Number | Description | |
101.INS
|
XBRL Instance Document. | |
|
||
101.SCH
|
XBRL Taxonomy Extension Schema. | |
|
||
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase | |
|
||
101.LAB
|
XBRL Taxonomy Extension Labels Linkbase. | |
|
||
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase. |
1
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MOLECULAR PHARMACOLOGY (USA) LIMITED | ||
BY: |
/s/ Jeffrey D. Edwards
|
|
Jeffrey D. Edwards, President and Chief Executive Officer, Chief Financial Officer and Member of the Board of Directors | ||
Date: | October 18, 2011 | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
BY: |
/s/ Jeffrey D. Edwards
|
|
Jeffrey D. Edwards, President and Chief Executive Officer, Chief Financial Officer and Member of the Board of Directors | ||
Date: | October 18, 2011 | |
2
1 Year Molecular Pharmacology (PK) Chart |
1 Month Molecular Pharmacology (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions